Gables Capital Management’s AstraZeneca AZN Stock Holding History

Gables Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.4K	Buy	+287	New	+$54K	0.02%	243
2024 Q1	–	Sell	-125	Closed	-$16.8K	–	392
2023 Q4	$16.8K	Hold	125	–	–	0.01%	270
2023 Q3	$16.9K	Hold	125	–	–	0.01%	255
2023 Q2	$17.9K	Sell	125 -18	-13%	-$2.65K	0.01%	262
2023 Q1	$19.8K	Buy	143 +18	+14%	+$2.42K	0.01%	251
2022 Q4	$16.9K	Hold	125	–	–	0.01%	253
2022 Q3	$14K	Hold	125	–	–	0.01%	255
2022 Q2	$17K	Hold	125	–	–	0.01%	262
2022 Q1	$17K	Hold	125	–	–	0.01%	263
2021 Q4	$15K	Hold	125	–	–	0.01%	278
2021 Q3	$15K	Hold	125	–	–	0.01%	279
2021 Q2	$15K	Hold	125	–	–	0.01%	280
2021 Q1	$12K	Hold	125	–	–	0.01%	310
2020 Q4	$12K	Hold	125	–	–	0.01%	302
2020 Q3	$14K	Buy	125 +75	+150%	+$8.34K	0.01%	287
2020 Q2	$5K	Buy	+50	New	+$5.16K	﹤0.01%	318

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Gables Capital Management's AZN Position: Q2 2026 in Review

Gables Capital Management opened a new position in AstraZeneca (AZN) in Q2 2026: 287 shares worth $54.4K. The stake represents 0.02% of the portfolio and ranks #243 among its holdings. This is a return to the name: Gables Capital Management previously reported a position in AZN as recently as Q4 2023.

Gables Capital Management first reported a position in AZN in Q2 2020 and has held it in 16 quarters since. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Gables Capital Management held 287 shares of AstraZeneca worth $54.4K as of Q2 2026.
AstraZeneca was a new Gables Capital Management position in Q2 2026.
AstraZeneca made up 0.02% of Gables Capital Management's portfolio in Q2 2026, its #243 holding.
Gables Capital Management first reported a position in AstraZeneca in Q2 2020 and has held it in 16 quarters since.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.